Now behind us: 3rd International AMR Matchmaking Symposium 19-20 November, Amsterdam, Netherlands >>

Partners AMR Insights

For its global activities AMR Insights is dependent on its highly valued partners.

Download sponsoring opportunities 2019 here

Current partners:

Resistell proposes an alternative to culture based antibiogram, the current gold standard in antibiotic susceptibility testing. The rapid AST method is based on the detection of movement caused by living bacterial cells. Resistell was selected in the Top 3 Inventors category at the Swiss Technology Award 2018.

BiosparQ B.V. is a privately-held in vitro diagnostics company dedicated to providing a unique Technology called DigiTOF® that improves patient outcomes and lowers healthcare costs through enabling clinicians to speed up diagnosis of infections.

The Cirrus D20 system is a platform intended for the rapid and cost-effective detection and identification of infectious pathogens. DigiTOF® is based on MALDI-TOF Mass Spectrometry
applied on single bacteria isolated directly from patient material. Easy to use, overall less than
20 minutes turnaround time and low cost per test.

Addressing the human health impacts of AMR will require building a strong and motivated coalition of like-minded health officials, clinicians, laboratorians, policymakers, patients and leaders.

NYtor (2007) designs and (co-)develops smart, molecular assays for detecting antibiotic resistance in human and veterinary diagnostics. Design and co-development take place in close collaboration with customers, selected suppliers and global partners. NYtor also produces its prototype assays.

To make a difference in the lives of people globally through our innovative medicines, vaccines, and animal health products. We are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.

BSAC is a leading influencer of antimicrobial use globally, and has been since the Society was founded in 1971.  BSAC has members across 6 continents and in 40 countries, with over 60,000 learners in 37,500 learner locations engaged in its open access e-learning programme.  BSAC publishes the Journal of Antimicrobial Chemotherapy and JAC-Antimicrobial Resistance (JAC-AMR).

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!